Picture of Ironwood Pharmaceuticals logo

IRWD — Ironwood Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapNeutral

Ironwood Pharmaceuticals Inc expected to post earnings of 24  cents a share - Earnings Preview

* Ironwood Pharmaceuticals Inc  IRWD.OQ   IRWD.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 4. 
    * The Boston Massachusetts-based  company is expected to
report  a
3.0% increase in revenue to $100.41 million from $97.53 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Ironwood
Pharmaceuticals
Inc is for earnings of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 6.9%
in the last three months. ​
    * Wall Street's median 12-month price target for Ironwood
Pharmaceuticals Inc is $13​, above​ its last closing price
of $10.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  0.26        0.27       0.27      Met     0
 Sep. 30 2022  0.26        0.27       0.28      Beat    5.7
 Jun. 30 2022  0.30        0.30       0.21      Missed  -28.8​
 Mar. 31 2022  0.25        0.26       0.21      Missed  -17.6
 ​​Dec.        0.36        0.35       0.27      Missed  -23.6
 31 2021                                                
 Sep. 30 2021  0.31        0.31       0.33      Beat    6.5​
 Jun. 30 2021  0.23        0.23       0.34      Beat    47.8
 Mar. 31 2021  0.22        0.21       0.24      Beat    16.5
 This summary was machine generated May 2 at 18:35 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Ironwood Pharmaceuticals

See all news